Ceratium collaborate with a strong European consortium to develop another winning H2020 proposal.
The TIGER project will combine exciting mRNA-based immunotherapies with cutting edge nanomedicine technologies to target hard to treat cancers. Ceratium’s Dr Ritchie Head led the Stage 2 proposal writing assisted by Christina Olsen refining the project’s clinical studies strategy for the proposal and working closely with the eTheRNA team and partners.
“The Ceratium team are thrilled to be part of this project knowing our hard work at proposal stage has paid off. TIGER brings together some of the most exciting technologies we have come across and offers the potential for new oncology treatments and decision tools”. - Ritchie Head, MD of Ceratium BV
The TIGER project (Grant 945011) will co-fund a phase I/IIa clinical study for eTheRNA’s novel Intra Venous mRNA Lipid Nanoparticle (LNP) product. The antigens comprise mRNAs encoding the HPV16 proteins E6 and E7 and eTheRNA’s proprietary TriMix mRNAs. TriMix acts as an adjuvant to activate dendritic cells to induce strong T-cell responses to the antigens.
“eTheRNA and its collaborators welcome the award of this grant. In addition to HPV, this collaboration will investigate the possibility of applying mRNA technologies to the treatment of other cancer indications with poorly met medical needs”. - Marina Cools, VP of Clinical Development at eTheRNA, commented
The phase I/IIa trials will target patients with recurrent/metastatic Human Papilloma Virus strain 16 positive (HPV16+) cancers such as head and neck cancer, cervical cancer, anogenital cancer. This study will assess safety, immunogenicity and clinical activity. eTheRNA will advance their next generation mRNA vaccines and in-house manufacturing. TIGER partners Radiomics will advance their AI driven, proprietary medical image analysis technology and SAGA Diagnostics will develop bespoke SAGAsafe® dPCR assays that will be used to monitor circulating tumor DNA (ctDNA) from patients at baseline and during treatment to measure treatment response.
“Representing the largest cancer patient community in Europe, ECPC will ensure that the patients’ perspective is heard throughout the implementation of the project. We strongly advocate the involvement of cancer patients in research projects as they provide invaluable understanding of the challenges that they face throughout their cancer journey.” - Antonella Cardone, Director of European Cancer Patient Coalition, commented
Representing participants from three countries, the consortium includes eTheRNA Immunotherapies, European Cancer Patient Coalition, Amsterdam University Medical Center, Saint-Luc University Clinics, SAGA Diagnostics, Radiomics and Patergrus, in addition to Ceratium BV. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 945011.